Tom Lillie MD, PhD

Tom Lillie is the Vice President and Head of European Clinical Development for Merck, Sharp and Dohme. Dr Lillie completed his undergraduate training at Brasenose College, University of Oxford, where he was awarded a first class degree in pharmacology, cell biology and immunology, before earning his doctorate from the Department of Physiology at the University College of London. He then completed his medical education at the University College London Medical School, receiving honors distinction in clinical pharmacology and surgery. He is a member of the Royal College of Surgeons of England and the Faculty of Pharmaceutical Medicine of the Royal College of Physicians.

Tom has led global, regional and affiliate medical teams, encompassing both clinical development and medical affairs functions. He has extensive experience in clinical research in phase 2 – phase 4, and in supporting regulatory, safety and reimbursement interactions. During his clinical and industry career he has specialised in oncology & haematology, but has also worked in cardiovascular and neurologic disease areas.